tirzepatide and hfpef At #ACC25, Dr. Milton Packer colleagues present a new secondary analysis from the SUMMIT trial evaluating the effect of in patients with obesity, #HFpEF, and CKD. The trial demonstrated that # Tirzepatide cuts heart failure risk

Prime Therapeutics research Two years, ago, Prime began an analysis to determine the return on investment from a total cost of care perspective when it comes to GLP-1s for weight loss

Consistency matters more than dose

And heres an important point

Almost four decades later, Winfrey is part of a relatively new and ongoing cultural revolution in how doctors, patients, and families think about weight, and specifically, obesity as a chronic disease

This ensures your plan is rooted in medical understanding, not assumptions

Tirzepatide has very recently received approval in Japan, as well as in the US and Europe, for the treatment of obesity